Director/PDMR Shareholding

RNS Number : 7099Y

Advanced Medical Solutions Grp PLC

14 May 2021

 

14 May 2021

  Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

  Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company , announces that the Trust which manages the Deferred Share Bonus Plan ("DSB") on behalf of the employees of AMS has purchased ordinary shares of 5 pence each ("Ordinary Shares") on 11 May 2021, at a price of 272.09p on behalf of Chris Meredith and Eddie Johnson, who are both Directors and PDMRs, as part of the DSB and, under the terms of the DSB, these shares will be held in trust on their behalf.

The announcement made on 14 April 2021 explained that Chris Meredith and Eddie Johnson were selling shares, the p roceeds of which would be used to purchase shares in the DSB. The purchases outlined above complete that process.

Following these transactions the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:

Director/PDMR	Date purchased	Shares purchased (through DSB)	Resultant holding	% of issued share capital
Chris Meredith Chief Executive Officer	11 May 2021	13,855	1,523,900	0.7%
Eddie Johnson Chief Financial Officer	11 May 2021	9,606	75,634	0.03%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Chris Meredith
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:  Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: · Purchase of 13,855 Ordinary Shares as part of the Deferred Share Bonus Plan on 11 May 2021 at a price of 272.09p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) n/a n/a
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a
e)	Date of the transaction: 11/05/2021
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Eddie Johnson
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:  Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: · Purchase of 9,606 Ordinary Shares as part of the Deferred Share Bonus Plan on 11 May 2021 at a price of 272.09p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) n/a n/a
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a
e)	Date of the transaction: 11/05/2021
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

-End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott / Matthew Neal / Matthew Cole	[e-mail]
Investec Bank PLC (NOMAD & Broker)	Tel: [phone]
Daniel Adams / Gary Clarence / Patrick Robb

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^® and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com

 

END

 

 

DSHBBGDUIGBDGBS